文献速递血栓与止血

阿伐曲泊帕治疗免疫性血小板减少症:西班牙ITP组(GEPTI)的真实世界研究

Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
PubMed 文献 · Am J Hematol · 2024-10-12

西班牙ITP组(GEPTI)开展回顾性研究,纳入268例首次启用阿伐曲泊帕的ITP患者,中位随访47.5周。基线血小板<50×10^9/L的193例中174例(90.1%)获得缓解;基线≥50×10^9/L的75例中73例(97.3%)报告缓解。研究支持阿伐曲泊帕用于ITP管理,不受疾病严重程度和治疗史影响。

要点

  • 基线血小板<50×10^9/L患者中90.1%(174/193)获得缓解(血小板≥50×10^9/L)。
  • 基线血小板≥50×10^9/L患者中97.3%(73/75)报告缓解。
  • 总体血栓事件12/268(4.5%),血小板增多症40/268(14.9%)。

核心结论

  • 真实世界队列支持使用阿伐曲泊帕管理ITP,不受疾病严重程度和治疗史影响。

研究设计与样本

  • 西班牙ITP组(GEPTI)开展的回顾性研究,纳入268例首次开始阿伐曲泊帕治疗的ITP患者,中位随访47.5周(IQR 30.4-58.9)。

主要发现

  • 基线血小板<50×10^9/L的193例中174例(90.1%)获得缓解(血小板≥50×10^9/L);末次访视时持续使用阿伐曲泊帕的129例中113例(87.6%)血小板高于该阈值。
  • 仅纳入因既往治疗失败而换用阿伐曲泊帕的患者(n=104)时结果相似;患者在中位13天(IQR 7-21)达到缓解。
  • 基线血小板≥50×10^9/L的75例中73例(97.3%)报告缓解,研究结束时持续用药的56例中53例(94.6%)维持缓解。
  • 基线血小板<50×10^9/L且既往治疗失败后换药的重度经治(≥4线)患者中,约79%(34/43)达到血小板≥50×10^9/L。
  • 基线血小板<50×10^9/L的50例中40例(80.0%)得以减量或停用糖皮质激素;总体报告血小板增多症40/268(14.9%)和血栓栓塞事件12/268(4.5%)。

关键数值与推荐

  • 缓解定义为血小板≥50×10^9/L。
  • 失应答率始终<10%。
  • ITP病程不影响缓解;既往使用艾曲泊帕和/或罗米司亭不影响缓解,无论既往TPO-RA成功或失败。

临床怎么用

  • 原文结论为真实世界队列支持使用阿伐曲泊帕管理ITP,不受疾病严重程度和治疗史影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow-up time was 47.5 (30.4-58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7-21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss-of-response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO-RA(s) succeeded or failed. Avatrombopag allowed dose-reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pascual-Izquierdo C, Sánchez-González B, Canaro-Hirnyk MI, et al. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI). Am J Hematol. 2024. PMID: 39394928. doi:10.1002/ajh.27498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。